recombinant lipase (CDX-7108) / Codexis, Nestle - LARVOL DELTA

Oral CDX-7108 in Healthy Adults and EPI Subjects (clinicaltrials.gov) - P1 | N=54 | Completed | Sponsor: Société des Produits Nestlé (SPN) | Phase classification: P1a/1b ➔ P1

Phase classification • CRP • ELANE

Oral CDX-7108 in Healthy Adults and EPI Subjects (clinicaltrials.gov) - P1a/1b | N=54 | Completed | Sponsor: Société des Produits Nestlé (SPN) | Recruiting ➔ Completed | Trial completion date: Jan 2024 ➔ Mar 2023 | Trial primary completion date: Jun 2023 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • CRP • ELANE

Oral CDX-7108 in Healthy Adults and EPI Subjects (clinicaltrials.gov) - P1a/1b | N=58 | Recruiting | Sponsor: Nestlé | Trial completion date: Feb 2023 ➔ Jan 2024 | Trial primary completion date: Jul 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • CRP • ELANE

Oral CDX-7108 in Healthy Adults and EPI Subjects (clinicaltrials.gov) - P1a/1b; N=58; Recruiting; Sponsor: Nestlé; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CRP • ELANE

Oral CDX-7108 in Healthy Adults and EPI Subjects (clinicaltrials.gov) - P1a/1b; N=58; Not yet recruiting; Sponsor: Nestlé

Clinical • New P1 trial • CRP • ELANE